Our findings in HUVEC suggested the same downstream effects on the gene signature for GTF2E1 inhibition as that of FLT1 (i.e., a molecular mediator of preeclampsia symptoms [5]) inhibition with the altered gene signature mimicking preeclampsia development. The gene discussed is FLT1; the disease is preeclampsia.